Loading
A Chinese study comparing DNA methylation, DNA mutations and proteins in blood found methylation the strongest signal for nine cancers, with proteins adding some extra cancers.
PROMISE (NCT04972201) prospectively collected blood from 1,706 participants (866 with one of nine cancers, 840 without), split into training and validation sets. The methylation classifier outperformed mutation-based and protein-based classifiers; 95.0% of cancers detected by mutations were also detected by methylation. Combining methylation and protein features raised sensitivity to 75.1% (69.3 to 80.3) at the same 98.8% specificity, with 73.1% accuracy for the top predicted origin.
Supports the design choice of most current tests: methylation first, with proteins as an add-on rather than mutations.
Shares OverC Multi-Cancer Detection Blood Test, Burning Rock Biotech, Cell-free DNA methylation tests, Multi-cancer early detection (MCED).
Shares OverC Multi-Cancer Detection Blood Test, Burning Rock Biotech, Multi-cancer early detection (MCED).
Shares OverC Multi-Cancer Detection Blood Test, Burning Rock Biotech, Multi-cancer early detection (MCED).
Shares OverC Multi-Cancer Detection Blood Test, Burning Rock Biotech, Multi-cancer early detection (MCED).
Shares Burning Rock Biotech, Multi-cancer early detection (MCED).
Shares Cell-free DNA methylation tests, Proteomics & phosphoproteomics, Multi-cancer early detection (MCED).
Shares Burning Rock Biotech, Multi-cancer early detection (MCED).
Shares Burning Rock Biotech, Multi-cancer early detection (MCED).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/